Billionaire Larry Robbins’ Long-Term Stock Picks

Page 6 of 15

10. Myriad Genetics, Inc. (NASDAQ:MYGN)

Number of Hedge Fund Holders: 23

Glenview Capital’s Stake: $34.6 million

Myriad Genetics, Inc. (NASDAQ:MYGN) is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. This company presents a solid investment opportunity, supported by the following points. To begin, the report for the third quarter of 2024 showed an 11% increase in revenue year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives. This indicates the company’s successful expansion in key areas and effective execution of strategic initiatives. Secondly, the company’s collaboration with Flatiron Health aims to expand the possibilities of point-of-care solutions in oncology. This collaboration allows physicians to order Myriad’s MyRisk Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based Electronic Medical Record (EMR) platform, OncoEMR. MyRisk is the first hereditary cancer test to be incorporated into Flatiron’s OncoEMR. Moreover, the company has collaborated with GSK, aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients.

Page 6 of 15